921 related articles for article (PubMed ID: 14635068)
1. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
Potters L; Purrazzella R; Brustein S; Fearn P; Leibel SA; Kattan MW
Cancer; 2002 Oct; 95(7):1451-6. PubMed ID: 12237913
[TBL] [Abstract][Full Text] [Related]
4. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
Kausik SJ; Blute ML; Sebo TJ; Leibovich BC; Bergstralh EJ; Slezak J; Zincke H
Cancer; 2002 Sep; 95(6):1215-9. PubMed ID: 12216087
[TBL] [Abstract][Full Text] [Related]
6. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
7. Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer.
Elliott SP; Shinohara K; Logan SL; Carroll PR
J Urol; 2002 Jul; 168(1):105-9. PubMed ID: 12050501
[TBL] [Abstract][Full Text] [Related]
8. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
9. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
10. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2010 Jun; 105(11):1541-7. PubMed ID: 19912191
[TBL] [Abstract][Full Text] [Related]
11. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
Reese AC; Cooperberg MR; Carroll PR
J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578
[TBL] [Abstract][Full Text] [Related]
12. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
[TBL] [Abstract][Full Text] [Related]
13. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.
Olsson CA; de Vries GM; Raffo AJ; Benson MC; O'Toole K; Cao Y; Buttyan RE; Katz AE
J Urol; 1996 May; 155(5):1557-62. PubMed ID: 8627821
[TBL] [Abstract][Full Text] [Related]
14. The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomy.
Barlow LJ; Badalato GM; Bashir T; Benson MC; McKiernan JM
BJU Int; 2010 Jun; 105(12):1646-9. PubMed ID: 19863523
[TBL] [Abstract][Full Text] [Related]
15. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
J Urol; 1995 Jul; 154(1):131-8. PubMed ID: 7539857
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
17. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population.
Lewis JS; Vollmer RT; Humphrey PA
Am J Clin Pathol; 2002 Sep; 118(3):442-50. PubMed ID: 12219787
[TBL] [Abstract][Full Text] [Related]
18. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
Smith EB; Frierson HF; Mills SE; Boyd JC; Theodorescu D
Cancer; 2002 Apr; 94(8):2282-7. PubMed ID: 12001128
[TBL] [Abstract][Full Text] [Related]
19. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis.
Cupp MR; Bostwick DG; Myers RP; Oesterling JE
J Urol; 1995 May; 153(5):1543-8. PubMed ID: 7714976
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Djavan B; Ravery V; Zlotta A; Dobronski P; Dobrovits M; Fakhari M; Seitz C; Susani M; Borkowski A; Boccon-Gibod L; Schulman CC; Marberger M
J Urol; 2001 Nov; 166(5):1679-83. PubMed ID: 11586201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
